Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P35236
UPID:
PTN7_HUMAN
Alternative names:
Hematopoietic protein-tyrosine phosphatase; Protein-tyrosine phosphatase LC-PTP
Alternative UPACC:
P35236; B3KXE1; Q53XK4; Q5SXQ0; Q5SXQ1; Q9BV05
Background:
Tyrosine-protein phosphatase non-receptor type 7, also known as Hematopoietic protein-tyrosine phosphatase or Protein-tyrosine phosphatase LC-PTP, encoded by the gene with accession number P35236, is a pivotal enzyme in cellular signaling. It preferentially dephosphorylates tyrosine-phosphorylated MAPK1, playing a crucial role in the regulation of T and B-lymphocyte development and signal transduction.
Therapeutic significance:
Understanding the role of Tyrosine-protein phosphatase non-receptor type 7 could open doors to potential therapeutic strategies. Its critical function in lymphocyte development and signal transduction positions it as a key target for modulating immune responses.